BioSpace News Archive

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

BioInvent International Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in the dose escalation phase.

Spago Nanomedical Spago Nanomedical AB announced the establishment of a Scientific Advisory Board comprised of scientific and clinical leaders in oncology and nuclear medicine.

AlzeCure Pharma AB announced that a new scientific article on preclinical results supporting a disease-modifying effect with NeuroRestore ACD856 has been made available online.

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced the U.S. Food and Drug Administration has granted clearance of the company’s Investigational New Drug application for HF158K1, a drug encapsulated immunoliposome containing doxorubicin.

DEM BioPharma, Inc., an immune-oncology company developing therapies that target signals on cancer cells and myeloid phagocytes to eliminate cancer, announced the addition of Wendy Young, Ph.D., to its Scientific Advisory Board.

Alkermes plc issued a letter to its shareholders in connection with the Company’s upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on June 20th, 2023 at 12:30 p.m. ET.

LEXEO Therapeutics announced the completion of the first dose cohort and the dosing of the first patient in the second dose cohort in SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 in patients with Friedreich’s ataxia cardiomyopathy.

Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland.